Follow
Liying Zhang, Ph.D
Liying Zhang, Ph.D
Sunnybrook Health Sciences Centre
Verified email at utoronto.ca
Title
Cited by
Cited by
Year
Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer
L Klotz, L Zhang, A Lam, R Nam, A Mamedov, A Loblaw
Journal of Clinical Oncology 28 (1), 126-131, 2010
13812010
Long-term follow-up of a large active surveillance cohort of patients with prostate cancer
L Klotz, D Vesprini, P Sethukavalan, V Jethava, L Zhang, S Jain, ...
Journal of Clinical Oncology 33 (3), 272-277, 2015
13332015
CT angiography clot burden score and collateral score: correlation with clinical and radiologic outcomes in acute middle cerebral artery infarct
IYL Tan, AM Demchuk, J Hopyan, L Zhang, D Gladstone, K Wong, ...
American Journal of Neuroradiology 30 (3), 525-531, 2009
7442009
Celiac disease: summary
A Rostom, C Dubé, A Cranney, N Saloojee, R Sy, C Garritty, M Sampson, ...
AHRQ evidence report summaries, 2004
4702004
Risk of developing retinopathy in Diabetes Control and Complications Trial type 1 diabetic patients with good or poor metabolic control
LY Zhang, G Krzentowski, A Albert, PJ Lefebvre
Diabetes care 24 (7), 1275-1279, 2001
3392001
Hereditary diffuse gastric cancer: updated clinical practice guidelines
VR Blair, M McLeod, F Carneiro, DG Coit, JL D'Addario, JM van Dieren, ...
The Lancet Oncology 21 (8), e386-e397, 2020
3302020
Genetic predictors of response to systemic therapy in esophagogastric cancer
YY Janjigian, F Sanchez-Vega, P Jonsson, WK Chatila, JF Hechtman, ...
Cancer discovery 8 (1), 49-58, 2018
3302018
Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data
S Middha, L Zhang, K Nafa, G Jayakumaran, D Wong, HR Kim, ...
JCO precision oncology 1, 1-17, 2017
3252017
Hemorrhagic Transformation of Ischemic Stroke: Prediction with CT Perfusion1
RI Aviv, CD d'Esterre, BD Murphy, JJ Hopyan, B Buck, G Mallia, V Li, ...
Radiology 250 (3), 867-877, 2009
2442009
Active surveillance for intermediate risk prostate cancer: survival outcomes in the Sunnybrook experience
HB Musunuru, T Yamamoto, L Klotz, G Ghanem, A Mamedov, ...
The Journal of urology 196 (6), 1651-1658, 2016
2072016
Quality of life (QOL) and symptom burden (SB) in patients with breast cancer
J Hamer, R McDonald, L Zhang, S Verma, A Leahey, C Ecclestone, ...
Supportive Care in Cancer 25, 409-419, 2017
1962017
Certainty of stroke diagnosis: incremental benefit with CT perfusion over noncontrast CT and CT angiography
J Hopyan, A Ciarallo, D Dowlatshahi, P Howard, V John, R Yeung, ...
Radiology 255 (1), 142-153, 2010
1862010
Prostate stereotactic ablative body radiotherapy using a standard linear accelerator: toxicity, biochemical, and pathological outcomes
A Loblaw, P Cheung, L D’Alimonte, A Deabreu, A Mamedov, L Zhang, ...
Radiotherapy and Oncology 107 (2), 153-158, 2013
1822013
Active surveillance for prostate cancer: a narrative review of clinical guidelines
SM Bruinsma, CH Bangma, PR Carroll, MS Leapman, A Rannikko, ...
Nature Reviews Urology 13 (3), 151-167, 2016
1812016
Determining the incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: results from three canadian cancer centers
A Hird, E Chow, L Zhang, R Wong, J Wu, E Sinclair, C Danjoux, M Tsao, ...
International Journal of Radiation Oncology* Biology* Physics 75 (1), 193-197, 2009
1682009
High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's Lymphoma
R Buckstein, RS Kerbel, Y Shaked, R Nayar, C Foden, R Turner, CR Lee, ...
Clinical cancer research 12 (17), 5190-5198, 2006
1632006
ClinGen Myeloid Malignancy Variant Curation Expert Panel recommendations for germline RUNX1 variants
X Luo, S Feurstein, S Mohan, CC Porter, SA Jackson, S Keel, M Chicka, ...
Blood advances 3 (20), 2962-2979, 2019
1332019
Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction …
JM Hudson, A Loblaw, M McGuffin, HT Chung, CL Tseng, J Helou, ...
Radiotherapy and Oncology, 110381, 2024
1292024
Frequency of reporting and predictive factors for anxiety and depression in patients with advanced cancer
N Salvo, L Zeng, L Zhang, M Leung, L Khan, R Presutti, J Nguyen, ...
Clinical Oncology 24 (2), 139-148, 2012
1252012
Specifications of the ACMG/AMP variant interpretation guidelines for germline TP53 variants
C Fortuno, K Lee, M Olivier, T Pesaran, PL Mai, KC de Andrade, ...
Human mutation 42 (3), 223-236, 2021
1212021
The system can't perform the operation now. Try again later.
Articles 1–20